Life Edit Therapeutics
Nick Keul is a proficient scientist currently holding the position of Scientist II in Technology Development at Life Edit Therapeutics since October 2023. Prior to this role, Nick served as a Scientist I focusing on Biochemistry and Protein Engineering at Cellibre from July 2019. Nick's academic background includes a PhD in Biochemistry, Biophysics, and Molecular Biology from the University of Georgia, as well as dual bachelor's degrees in Biochemistry and Molecular Biology from Virginia Tech. Nick's extensive research experience spans protein expression and purification, assay development, and bioinformatics, complemented by programming skills in Perl and Python. Notable previous positions include Graduate Research Assistant at the University of Georgia and Undergraduate Research Assistant at The Fralin Life Sciences Institute at Virginia Tech.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.